Erratum: Hyperinsulinaemic androgen excess in adolescent girls (Nature Reviews Endocrinology (2014) 10 (499-508) DOI: 10.1038/nrendo.2014.58);Hyperinsulinaemic androgen excess in adolescent girls

Nature Reviews Endocrinology

Volumn 10, Issue 8, 2014, Pages 499-508

  Ibáñez, Lourdes ^a   Ong, Ken K ^b   López Bermejo, Abel ^d   Dunger, David B ^c   De Zegher, Francis ^e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d HOSPITAL JOSEP TRUETA   (Spain)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; CYPROTERONE ACETATE; DESOGESTREL; DROSPIRENONE; ESTRADIOL; FLUTAMIDE; GESTAGEN; GESTODENE; GONADOTROPIN; INSULIN; INSULIN SENSITIZING AGENT; LEVONORGESTREL; LIPID; METFORMIN; NORETHISTERONE; NORGESTIMATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; SPIRONOLACTONE;

ADIPOSE TISSUE; ADOLESCENCE; ANDROGEN RELEASE; CLINICAL ASSESSMENT; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE SUBFERTILITY; GENETIC ASSOCIATION; GENOTYPE; GONADOTROPIN RELEASE; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MENSTRUAL IRREGULARITY; OBESITY; ORAL CONTRACEPTION; PRIORITY JOURNAL; REVIEW; VULNERABLE POPULATION;

ADOLESCENT; ANDROGENS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FLUTAMIDE; HIRSUTISM; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; MENSTRUATION DISTURBANCES; METFORMIN; OBESITY; THIAZOLIDINEDIONES;

EID: 84904723213     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.132     Document Type: Erratum

References (167)

1. Burghen, G. A., Givens, J. R. & Kitabchi, A. E. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 50, 113-116 (1980).
2. Chang, R. J., Nakamura, R. M., Judd, H. L. & Kaplan, S. A. Insulin resistance in nonobese patients with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 57, 356-359 (1983).
3. Barbieri, R. L., Smith, S. & Ryan, K. J. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil. Steril. 50, 197-212 (1988).
4. Dunaif, A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 18, 774-800 (1997).
5. de Zegher, F., López-Bermejo, A. & Ibáñez, L. Adipose tissue expandability and the early origins of PCOS. Trends Endocrinol. Metab. 20, 418-423 (2009).
6. National Institutes of Health. Evidence-based methodology workshop on polycystic ovary syndrome, December 3-5, 2012, Final report [online], https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf.
7. Zawadzki, J. K. & Dunaif, A. in Polycystic Ovary Syndrome (eds Dunaif, A. et al.) 377-384 (Blackwell Scientific publications, 1992).
8. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41-47 (2004).
9. Azziz, R. et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456-488 (2009).
10. Vilmann, L. S., Thisted, E., Baker, J. L. & Holm, J. C. Development of obesity and polycystic ovary syndrome in adolescents. Horm. Res. Paediatr. 78, 269-278 (2012).
11. Rosenfield, R. L. Clinical review: Adolescent anovulation: maturational mechanisms and implications. J. Clin. Endocrinol. Metab. 98, 3572-3583 (2013).
12. Christensen, S. B. et al. Prevalence of polycystic ovary syndrome in adolescents. Fertil. Steril. 100, 470-477 (2013).
13. Legro, R. et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 98, 4565-4592 (2013).
14. Li, L. et al. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents. J. Pediatr. Adolesc. Gynecol. 25, 390-395 (2012).
15. Nidhi, R., Padmalatha, V., Nagarathna, R. & Amritanshu, R. Prevalence of polycystic ovarian syndrome in Indian adolescents. J. Pediatr. Adolesc. Gynecol. 24, 223-227 (2011).
16. Corbett, S. J., McMichael, A. J. & Prentice, A. M. Type 2 diabetes, cardiovascular disease, and the evolutionary paradox of the polycystic ovary syndrome: a fertility first hypothesis. Am. J. Hum. Biol. 21, 587-598 (2009).
17. Corbett, S. & Morin-Papunen, L. The polycystic ovary syndrome and recent human evolution. Mol. Cell. Endocrinol. 373, 39-50 (2013).
18. Rich-Edwards, J. W. et al. Physical activity, body mass index, and ovulatory disorder infertility. Epidemiology 13, 184-190 (2002).
19. Fogel, R. W. The escape from hunger and premature death: Europe, America and the third world: 1700-2100 (Cambridge University Press, 2004).
20. Schmidhuber, J. & Shetty, P. Nutrition transition, obesity and noncommunicable diseases: drivers, outlook and concerns. SCN News 29, 13-19 (2004).
21. Bonhommeau, S. et al. Eating up the world's food web and the human trophic level. Proc. Natl Acad. Sci. USA 110, 20617-20620 (2013).
22. Ley, S. H. et al. Associations between red meat intake and biomarkers of inflammation and glucose metabolism in women. Am. J. Clin. Nutr. 99, 352-360 (2014).
23. Sniderman, A. D., Bhopal, R., Prabhakaran, D., Sarrafzadegan, N. & Tchernof, A. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. Int. J. Epidemiol. 36, 220-225 (2007).
24. Zhao, Y. & Qiao, J. Ethnic differences in the phenotypic expression of polycystic ovary syndrome. Steroids 78, 755-760 (2013).
25. Ibáñez, L., Potau, N., Francois, I. & de Zegher, F. Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J. Clin. Endocrinol. Metab. 83, 3558-3662 (1998).
26. Wells, J. C. Ethnic variability in adiposity, thrifty phenotypes and cardiometabolic risk: addressing the full range of ethnicity, including those of mixed ethnicity. Obes. Rev. 13 (Suppl. 2), 14-29 (2012).
27. de Zegher, F. et al. Abundance of circulating preadipocyte factor 1 in early life. Diabetes Care 35, 848-849 (2012).
28. Sebastiani, G. et al. Circulating follistatin in the human foetus at term birth. Pediatr. Obes. 7, 39-43 (2012).
29. UNICEF & WHO. Low birthweight: country, regional and global estimates [online], http://www.unicef.org/publications/files/low-birthweight-from-EY.pdf ( 2004).
30. Dunger, D. B., Ahmed, M. L. & Ong, K. K. Effects of obesity on growth and puberty. Best Pract. Res. Clin. Endocrinol. Metab. 19, 375-390 (2005).
31. Williams, R. M., Ong, K. K. & Dunger, D. B. Polycystic ovarian syndrome during puberty and adolescence. Mol. Cell. Endocrinol. 373, 61-67 (2013).
32. Ong, K. K. et al. Opposing influences of prenatal and postnatal weight gain on adrenarche in normal boys and girls. J. Clin. Endocrinol. Metab. 89, 2647-2651 (2004).
33. Ibáñez, L., Ong, K., Dunger, D. B. & de Zegher, F. Early development of adiposity and insulin resistance after catch-up weight gain in small-for-gestational-age children. J. Clin. Endocrinol. Metab. 91, 2153-2158 (2006).
34. Ong, K. K. et al. Infancy weight gain predicts childhood body fat and age at menarche in girls. J. Clin. Endocrinol. Metab. 94, 1527-1532 (2009).
35. Rosenfield, R. L. Clinical review: Identifying children at risk for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 787-796 (2007).
36. Ibáñez, L., López-Bermejo, A., Díaz, M., Suárez, L. & de Zegher, F. Low-birth weight children develop lower sex hormone binding globulin and higher dehydroepiandrosterone sulfate levels and aggravate their visceral adiposity and hypoadiponectinemia between six and eight years of age. J. Clin. Endocrinol. Metab. 94, 3696-3699 (2009).
37. Steckler, T., Wang, J., Bartol, F. F., Roy, S. K. & Padmanabhan, V. Fetal programming: prenatal testosterone treatment causes intrauterine growth retardation, reduces ovarian reserve and increases ovarian follicular recruitment. Endocrinology 146, 3185-3193 (2005).
38. Steckler, T. L., Herkimer, C., Dumesic, D. A. & Padmanabhan, V. Developmental programming: excess weight gain amplifies the effects of prenatal testosterone excess on reproductive cyclicity-implication for polycystic ovary syndrome. Endocrinology 150, 1456-1465 (2009).
39. Chazenbalk, G. et al. Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids 78, 920-926 (2013).
40. Abbott, D. H. & Bacha, F. Ontogeny of polycystic ovary syndrome and insulin resistance in utero and early childhood. Fertil. Steril. 100, 2-11 (2013).
41. Hickey, M. et al. The relationship between maternal and umbilical cord androgen levels and ovarian function in adolescence: a prospective cohort study. J. Clin. Endocrinol. Metab. 94, 3714-3720 (2009).
42. de Zegher, F. & Ibáñez, L. Early origins of polycystic ovary syndrome: hypotheses may change without notice. J. Clin. Endocrinol. Metab. 94, 3682-3685 (2009).
43. Ferrante, A. W. Jr. Macrophages, fat, and the emergence of immunometabolism. J. Clin. Invest. 123, 4992-4993 (2013).
44. Rosen, E. D. & Spiegelman, B. M. What we talk about when we talk about fat. Cell 156, 20-44 (2014).
45. Nightingale, C. M. et al. Influence of adiposity on insulin resistance and glycemia markers among U.K. children of South Asian, black African-Caribbean, and white European origin: child heart and health study in England. Diabetes Care 36, 1712-1719 (2013).
46. Apter, D., Bützow, T., Laughlin, G. A. & Yen, S. S. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J. Clin. Endocrinol. Metab. 80, 2966-2973 (1995).
47. Lewy, V. D., Danadian, K., Witchel, S. F. & Arslanian, S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J. Pediatr. 138, 38-44 (2001).
48. Flannery, C. A. et al. Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI. Pediatr. Diabetes 14, 42-49 (2013).
49. Wu, S., Divall, S., Wondisford, F. & Wolfe, A. Reproductive tissues maintain insulin sensitivity in diet-induced obesity. Diabetes 61, 114-123 (2012).
50. McCartney, C. R. et al. Maturation of luteinizing hormone (gonadotropin-releasing hormone) secretion across puberty: evidence for altered regulation in obese peripubertal girls. J. Clin. Endocrinol. Metab. 94, 56-66 (2009).
51. McCartney, C. R. et al. Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre-and early pubertal obese girls. J. Clin. Endocrinol. Metab. 92, 430-436 (2007).
52. Hernandez, E. R., Resnick, C. E., Holtzclaw, W. D., Payne, D. W. & Adashi, E. Y. Insulin as a regulator of androgen biosynthesis by cultured rat ovarian cells: cellular mechanism(s) underlying physiological and pharmacological hormonal actions. Endocrinology 122, 2034-2043 (1988).
53. Nestler, J. E. et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J. Clin. Endocrinol. Metab. 83, 2001-2005 (1998).
54. Brothers, K. J. et al. Rescue of obesity-induced infertility in female mice due to a pituitary-specific knockout of the insulin receptor. Cell Metab. 12, 295-305 (2010).
55. Wu, S. et al. Obesity induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes 63, 1270-1282 (2014)
56. Yildiz, B. O., Yarali, H., Oguz, H. & Bayraktar, M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88, 2031-2036 (2003).
57. Sam, S., Legro, R. S., Essah, P. A., Apridonidze, T. & Dunaif, A. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc. Natl Acad. Sci. USA 103, 7030-7035 (2006).
58. Ibáñez, L., Castell, C., Tresserras, R. & Potau, N. Increased prevalence of type 2 diabetes mellitus and impaired glucose tolerance in first-degree relatives of girls with a history of precocious pubarche. Clin. Endocrinol. (Oxf.) 51, 395-401 (1999).
59. Barber, T. M & Franks, S. Genetics of polycystic ovary syndrome. Front. Horm. Res. 40, 28-39 (2013).
60. Shi, Y. et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat. Genet. 44, 1020-1025 (2012).
61. Chen, Z. J. et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat. Genet. 43, 55-59 (2011).
62. Goodarzi, M. O. et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J. Med. Genet. 49, 90-95 (2012).
63. Aittomäki, K. et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 82, 959-968 (1995).
64. De Leener, A. et al. Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J. Clin. Endocrinol. Metab. 91, 555-562 (2006).
65. Almahbobi, G. et al. Functional integrity of granulosa cells from polycystic ovaries. Clin. Endocrinol. (Oxf.) 44, 571-580 (1996).
66. von Schnurbein, J. et al. Leptin substitution results in the induction of menstrual cycles in an adolescent with leptin deficiency and hypogonadotropic hypogonadism. Horm. Res. Paediatr. 77, 127-133 (2012).
67. Sen, A. et al. Androgens regulate ovarian follicular development by increasing follicle stimulating hormone receptor and microRNA-125b expression. Proc. Natl Acad. Sci. USA 111, 3008-3013 (2014).
68. Semple, R. K., Savage, D. B., Cochran, E. K., Gorden, P. & O'Rahilly, S. Genetic syndromes of severe insulin resistance. Endocr. Rev. 32, 498-514 (2011).
69. Ibáñez, L. et al. Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 88, 3333-3338 (2003).
70. Zhang, T. et al. Association of the CAG repeat polymorphisms in androgen receptor gene with polycystic ovary syndrome: a systematic review and meta-analysis. Gene 524, 161-167 (2013).
71. Diamanti-Kandarakis, E. et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84, 4006-4011 (1999).
72. Azziz, R. & Kashar-Miller, M. D. Family history as a risk factor for the polycystic ovary syndrome. J. Pediatr. Endocrinol. Metab. 13 (Suppl. 5), 1303-1306 (2000).
73. Gambineri, A. et al. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 53, 2353-2358 (2004).
74. American Academy of Pediatrics Committee on Adolescence; American College of Obstetricians and Gynecologists Committee on Adolescent Health Care, Diaz, A., Laufer, M. R. & Breech, L. L. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics 118, 2245-2250 (2006).
75. Metcalf, M. G., Skidmore, D. S., Lowry, G. F. & Mackenzie, J. A. Incidence of ovulation in the years after the menarche. J. Endocrinol. 97, 213-219 (1983).
76. van Hooff, M. H. et al. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum. Reprod. 19, 383-392 (2004).
77. Hickey, M. et al. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. Hum. Reprod. 26, 1469-1477 (2011).
78. Gambineri, A. et al. Prevalence of hyperandrogenic states in late adolescent and young women: epidemiological survey on Italian high-school students. J. Clin. Endocrinol. Metab. 98, 1641-1650 (2013).
79. Lim, S. S., Norman, R. J., Davies, M. J. & Moran, L. J. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes. Rev. 14, 95-109 (2013).
80. Merino, P. M., Codner, E. & Cassorla, F. A rational approach to the diagnosis of polycystic ovarian syndrome during adolescence. Arq. Bras. Endocrinol. Metabol. 55, 590-598 (2011).
81. Ferriman, D. & Gallwey, J. D. Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab. 21, 1440-1447 (1961).
82. DeUgarte, C. M., Woods, K. S., Bartolucci, A. A. & Azziz, R. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J. Clin. Endocrinol. Metab. 91, 1345-1350 (2006).
83. Zhao, X. et al. Defining hirsutism in Chinese women: a cross-sectional study. Fertil. Steril. 96, 792-796 (2011).
84. rd. Female adolescent hair disorders. J. Pediatr. Adolesc. Gynecol. 22, 271-281 (2009).
85. Roe, A. H, Prochaska, E., Smith, M., Sammel, M. & Dokras, A. Using the androgen excess-PCOS society criteria to diagnose polycystic ovary syndrome and the risk of metabolic syndrome in adolescents. J. Pediatr. 162, 937-941 (2013).
86. Welt, C. K. & Carmina, E. Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. J. Clin. Endocrinol. Metab. 98, 4629-4638 (2013).
87. Carmina, E., Oberfield, S. E. & Lobo, R. A. The diagnosis of polycystic ovary syndrome in adolescents. Am. J. Obstet. Gynecol. 203, 201.e1-201.e5 (2010).
88. Diamanti-Kandarakis, E. PCOS in adolescents. Best Pract. Res. Clin. Obstet. Gynaecol. 24, 173-183 (2010).
89. Nicandri, K. F. & Hoeger, K. Diagnosis and treatment of polycystic ovary syndrome in adolescents. Curr. Opin. Endocrinol. Diabetes Obes. 19, 497-504 (2012).
90. Fanelli, F. et al. Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in healthy normal-weight ovulatory and anovulatory late adolescent and young women. J. Clin. Endocrinol. Metab. 98, 3058-3067 (2013).
91. Ibáñez, L., Potau, N., Marcos, M. V. & de Zegher, F. Adrenal hyperandrogenism in adolescent girls with a history of low birthweight and precocious pubarche. Clin. Endocrinol. (Oxf.) 53, 523-527 (2000).
92. Armengaud, J. B. et al. Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche. J. Clin. Endocrinol. Metab. 94, 2835-2840 (2009).
93. Park, A. S. et al. Serum anti-Mullerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism. J. Clin. Endocrinol. Metab. 95, 1786-1792 (2010).
94. Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419 (1985).
95. Levy-Marchal, C. et al. Insulin resistance in children: consensus, perspective, and future directions. J. Clin. Endocrinol. Metab. 95, 5189-5198 (2010).
96. Venturoli, S. et al. Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr. Res. 38, 974-980 (1995).
97. Mortensen, M., Rosenfield, R. L. & Littlejohn, E. Functional significance of polycystic-size ovaries in healthy adolescents. J. Clin. Endocrinol. Metab. 91, 3786-3790 (2006).
98. Balen, A. H., Laven, J. S., Tan, S. L. & Dewailly, D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum. Reprod. Update 9, 505-514 (2003).
99. Ibáñez, L. et al. Polycystic ovaries in nonobese adolescents and young women with ovarian androgen excess: relation to prenatal growth. J. Clin. Endocrinol. Metab. 93, 196-199 (2008).
100. Dewailly, D. et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum. Reprod. Update http://dx.doi.org/10.1093/humupd/dmt061.
101. Sir-Petermann, T. et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 94, 1923-1930 (2009).
102. Ibáñez, L. et al. Insulin sensitisation for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. J. Clin. Endocrinol. Metab. 89, 4331-4337 (2004).
103. Ibáñez, L. et al. Metformin treatment to prevent early puberty in girls with precocious pubarche. J. Clin. Endocrinol. Metab. 91, 2888-2891 (2006).
104. Ibáñez, L., López-Bermejo, A., Diaz, M., Marcos, M. V. & de Zegher, F. Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. J. Clin. Endocrinol. Metab. 93, 1841-1845 (2008).
105. Ibáñez, L., López-Bermejo, A., Diaz, M., Marcos, M. V. & de Zegher, F. Pubertal metformin therapy to reduce total, visceral and hepatic adiposity. J. Pediatr. 156, 98.e1-102.e1 (2010).
106. Ibáñez, L., López-Bermejo, A., Diaz, M., Marcos, M. V. & de Zegher, F. Early metformin therapy to delay menarche and augment height in girls with precocious pubarche. Fertil. Steril. 95, 727-730 (2011).
107. Ibáñez, L., López-Bermejo, A., Díaz, M., Marcos, M. V. & de Zegher, F. Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J. Clin. Endocrinol. Metab. 96, E1262-E1267 (2011).
108. th Joint Meeting of Paediatric Endocrinology.
109. Centers for Disease Control and Prevention. Sexual experience and contraceptive use among female teens-United States, 1995, 2002, and 2006-2010 Centers for Disease Control and Prevention (CDC). MMWR Morb. Mortal. Wkly Rep. 61, 297-301 (2012).
110. Catteau-Jonard, S., Cortet-Rudelli, C., RichardProust, C. & Dewailly, D. Hyperandrogenism in adolescent girls. Endocr. Dev. 22, 181-193 (2012).
111. Moran, L. J., Hutchison, S. K., Norman, R. J. & Teede, H. J. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews, Issue 7. Art. No.: CD007506. http://dx.doi.org/10.1002/ 14651858.CD007506.pub3.
112. Lass, N., Kleber, M., Winkel, K., Wunsch, R. & Reinehr, T. Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J. Clin. Endocrinol. Metab. 96, 3533-3540 (2011).
113. Hoeger, K. et al. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J. Clin. Endocrinol. Metab. 93, 4299-4306 (2008).
114. Bhattacharya, S. M. & Jha, A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil. Steril. 98, 1053-1059 (2012).
115. De Leo, V. et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception 82, 276-280 (2010).
116. Mastorakos, G., Koliopoulos, C., Deligeoroglou, E., Diamanti-Kandarakis, E. & Creatsas, G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil. Steril. 85, 420-427 (2006).
117. Cinar, N., Harmanci, A., Bayraktar, M. & Yildiz, O. Ethynil-estradiol-drospirenone vs ethynil-estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 78, 379-384 (2013).
118. Mastorakos, G., Koliopoulos, C. & Creatsas, G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil. Steril. 77, 919-927 (2002).
119. Jones, D. R., Schmidt, R. J., Pickard, R. T., Foxworthy, P. S. & Eacho, P. I. Estrogen receptor-mediated repression of human hepatic lipase gene transcription. J. Lipid Res. 43, 383-391 (2002).
120. Ibáñez, L. et al. Oral contraception vs insulin sensitisation for 18 months in nonobese adolescents with androgen excess: post-treatment differences in C-reactive protein, intima-media thickness, visceral adiposity, insulin sensitivity, and menstrual regularity. J. Clin. Endocrinol. Metab. 98, E902-E907 (2013).
121. Tfayli, H., Ulnach, J. W., Lee, S., Sutton-Tyrrell, K. & Arslanian, S. Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors. J. Clin. Endocrinol. Metab. 96, 1311-1319 (2011).
122. Jourdan, C. et al. Normative values for intima-media thickness and distensibility of large arteries in healthy adolescents. J. Hypertens. 23, 1707-1715 (2005).
123. Gode, F. et al. Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethynil estradiol-cyproterone acetate. Arch. Gynecol. Obstet. 284, 923-929 (2011).
124. Ibáñez, L. et al. Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone- flutamide-metformin. J. Clin. Endocrinol. Metab. 96, 3361-3366 (2011).
125. Bonny, A. E., Secic, M. & Cromer, B. A. A longitudinal comparison of body composition changes in adolescent girls receiving hormonal contraception. J. Adolesc. Health 45, 423-425 (2009).
126. Berenson, A. B. & Rahman, M. Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use. Am. J. Obstet. Gynecol. 200, 329.e1-329.e8 (2009).
127. Ibáñez, L. & de Zegher, F. Ethinylestradiol- drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J. Clin. Endocrinol. Metab. 89, 1592-1597 (2004).
128. Aydin, K., Cinar, N., Aksoy, D. Y., Bozdag, G. & Yildiz, B. O. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. Contraception 87, 358-362 (2013).
129. Ibáñez, L., Díaz, M., López-Bermejo, A. & de Zegher, F. Divergent effects of ethinylestradiol-drospirenone and flutamide-metformin on follistatin in adolescents and women with hyperinsulinemic androgen excess. Gynecol. Endocrinol. 27, 197-198 (2011).
130. rd et al. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics 127, 347-357 (2011).
131. Lidegaard, Ø., Nielsen, L. H., Skovlund, C. W., Skjeldestad, F. E. & Løkkegaard, E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 343, d6423 (2011).
132. Raps, M. et al. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J. Thromb. Haemost. 10, 992-997 (2012).
133. Okoroh, E. M., Hooper, W. C., Atrash, H. K., Yusuf, H. R. & Boulet, S. L. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008. Am. J. Obstet. Gynecol. 207, 377.e1-377.e8 (2012).
134. Bird, S. T., Hartzema, A. G., Brophy, J. M., Etminan, M. & Delaney, J. A. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ 185, E115-E120 (2013).
135. Sidney, S. et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 87, 93-100 (2013).
136. Nestler, J. E. Metformin for the treatment of the polycystic ovary syndrome. N. Engl. J. Med. 358, 47-54 (2008).
137. Palomba, S., Falbo, A., Zullo, F. & Orio, F. Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. Rev. 30, 1-50 (2009).
138. Ibáñez, L., Valls, C., Potau, N., Marcos, M. V. & de Zegher, F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinism after precocious pubarche. J. Clin. Endocrinol. Metab. 85, 3526-3530 (2000).
139. Ibáñez, L. et al. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J. Clin. Endocrinol. Metab. 86, 3595-3598 (2001).
140. Ibáñez, L. et al. Additive effects of insulin-sensitizing and anti-androgen treatment in young, non-obese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J. Clin. Endocrinol. Metab. 87, 2870-2874 (2002).
141. Ibáñez, L., Jaramillo, A. M., Ferrer, A. & de Zegher, F. High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. Hum. Reprod. 20, 2457-2462 (2005).
142. Díaz, M. et al. Responsiveness to metformin in girls with androgen excess: collective influence of genetic polymorphisms. Fertil. Steril. 96, 208.e2-213.e2 (2011).
143. Swiglo, B. A. et al. Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J. Clin. Endocrinol. Metab. 93, 1153-1160 (2008).
144. Simard, J., Luthy, I., Guay, J., Bélanger, A. & Labrie, F. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol. Cell. Endocrinol. 44, 261-270 (1986).
145. Ibáñez, L., Potau, N., Marcos, M. V. & de Zegher, F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J. Clin. Endocrinol. Metab. 85, 3251-3255 (2000).
146. Azziz, R., Carmina, E. & Sawaya, M. E. Idiopathic hirsutism. Endocr. Rev. 21, 347-362 (2000).
147. de Zegher, F. & Ibáñez, L. Therapy: Low-dose flutamide for hirsutism: into the limelight, at last. Nat. Rev. Endocrinol. 6, 421-422 (2010).
148. Ganie, M. A. et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J. Clin. Endocrinol. Metab. 89, 2756-2762 (2004).
149. Ganie, M. A. et al. Improved efficacy of low dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six month, open label, randomized study. J. Clin. Endocrinol. Metab. 98, 3599-3607 (2013).
150. Ibáñez, L. & de Zegher, F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum. Reprod. Update 12, 243-252 (2006).
151. McInnes, K. J., Brown, K. A. & Hunger, N. I., Simpson, E. R. Regulation of LKB1 expression by sex hormones in adipocytes. Int. J. Obes. 36, 982-985 (2012).
152. Ibáñez, L. et al. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 88, 2600-2606 (2003).
153. Mitkov, M., Pehlivanov, B. & Terzieva, D. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 118, 209-213 (2005).
154. Bredella, M. A., McManus, S. & Misra, M. Impact of metformin monotherapy versus metformin with oestrogen-progesterone on lipids in adolescent girls with polycystic ovarian syndrome. Clin. Endocrinol. (Oxf.) 79, 199-203 (2013).
155. Harmanci, A., Cinar, N., Bayraktar, M. & Yildiz, B. O. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 78, 120-125 (2013).
156. Ibáñez, L. et al. Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. J. Clin. Endocrinol. Metab. 92, 1710-1714 (2007).
157. Ibáñez, L. et al. Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin. Clin. Endocrinol. (Oxf.) 68, 317-320 (2008).
158. Ibáñez, L. et al. Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months. Clin. Endocrinol. (Oxf.) 71, 351-357 (2009).
159. Choi, J. H. et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5. Nature 466, 451-456 (2010).
160. Choi, J. H. et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477, 477-481 (2011).
161. Azoulay, L. et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 344, e3645 (2012).
162. He, S. et al. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumor Biol. 35, 2095-2102 (2014)
163. Joham, A. E., Ranasinha, S., Zoungas, S., Moran, L. & Teede, H. J. Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. http://dx.doi.org/10. 1210/jc.2013-2007.
164. Centers for Disease Control and Prevention. United States Medical Eligibility Criteria (US MEC) for Contraceptive Use, 2010. Reproductive Health [online]. http://www.cdc.gov/reproductivehealth/UnintendedPregnancy/USMEC.htm (2014).
165. Faculty of Sexual and Reproductive Healthcare. UK medical eligibility criteria for contraceptive use [online], http://www.fsrh.org/pdfs/UKMEC2009.pdf ( 2009).
166. Winner, B. et al. Effectiveness of long-acting reversible contraception. N. Engl. J. Med. 366, 1998-2007 (2012).
167. Gordon, C. M. & Pitts, S. A. Approach to the adolescent requesting contraception. J. Clin. Endocrinol. Metab. 97, 9-15 (2012).